Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer

Bihong T. Chen, Taihao Jin, Sunita K. Patel, Ningrong Ye, Can Lan Sun, Huiyan Ma, Russell C. Rockne, James C. Root, Andrew Saykin, Tim A. Ahles, Andrei I. Holodny, Neal Prakash, Joanne Mortimer, James Waisman, Yuan Yuan, Daneng Li, George Somlo, Jessica Vazquez, Abrahm Levi, Heidi TanRichard Yang, Vani Katheria, Arti Hurria

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy in older women with breast cancer. Methods: We recruited 16 women aged ≥ 60 years with stage I–III breast cancers receiving adjuvant chemotherapy (CT) and 15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry. Results: The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically significantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, and left middle temporal gyrus (pFWE(family-wise error)-corrected < 0.05). The baseline GMD in left insula was positively correlated with the baseline list-sorting working memory score in the HC group (pFWE-corrected < 0.05). No correlation was observed for the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (pFWE-corrected < 0.05). Conclusions: Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is registered on ClinicalTrials.gov (NCT01992432).

Original languageEnglish (US)
JournalBreast Cancer Research and Treatment
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Adjuvant Chemotherapy
Breast Neoplasms
Drug Therapy
Control Groups
Brain
Gray Matter
Gyrus Cinguli
Temporal Lobe
Short-Term Memory
Neuroimaging
Cognition

Keywords

  • Breast cancer
  • Chemotherapy
  • Cognition
  • Gray matter density (GMD)
  • Voxel-based morphometry (VBM)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer. / Chen, Bihong T.; Jin, Taihao; Patel, Sunita K.; Ye, Ningrong; Sun, Can Lan; Ma, Huiyan; Rockne, Russell C.; Root, James C.; Saykin, Andrew; Ahles, Tim A.; Holodny, Andrei I.; Prakash, Neal; Mortimer, Joanne; Waisman, James; Yuan, Yuan; Li, Daneng; Somlo, George; Vazquez, Jessica; Levi, Abrahm; Tan, Heidi; Yang, Richard; Katheria, Vani; Hurria, Arti.

In: Breast Cancer Research and Treatment, 01.01.2018.

Research output: Contribution to journalArticle

Chen, BT, Jin, T, Patel, SK, Ye, N, Sun, CL, Ma, H, Rockne, RC, Root, JC, Saykin, A, Ahles, TA, Holodny, AI, Prakash, N, Mortimer, J, Waisman, J, Yuan, Y, Li, D, Somlo, G, Vazquez, J, Levi, A, Tan, H, Yang, R, Katheria, V & Hurria, A 2018, 'Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer', Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-018-4911-y
Chen, Bihong T. ; Jin, Taihao ; Patel, Sunita K. ; Ye, Ningrong ; Sun, Can Lan ; Ma, Huiyan ; Rockne, Russell C. ; Root, James C. ; Saykin, Andrew ; Ahles, Tim A. ; Holodny, Andrei I. ; Prakash, Neal ; Mortimer, Joanne ; Waisman, James ; Yuan, Yuan ; Li, Daneng ; Somlo, George ; Vazquez, Jessica ; Levi, Abrahm ; Tan, Heidi ; Yang, Richard ; Katheria, Vani ; Hurria, Arti. / Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer. In: Breast Cancer Research and Treatment. 2018.
@article{d3e2d61af4364ebabb78ada140a3e24e,
title = "Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer",
abstract = "Purpose: The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy in older women with breast cancer. Methods: We recruited 16 women aged ≥ 60 years with stage I–III breast cancers receiving adjuvant chemotherapy (CT) and 15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry. Results: The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically significantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, and left middle temporal gyrus (pFWE(family-wise error)-corrected < 0.05). The baseline GMD in left insula was positively correlated with the baseline list-sorting working memory score in the HC group (pFWE-corrected < 0.05). No correlation was observed for the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (pFWE-corrected < 0.05). Conclusions: Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is registered on ClinicalTrials.gov (NCT01992432).",
keywords = "Breast cancer, Chemotherapy, Cognition, Gray matter density (GMD), Voxel-based morphometry (VBM)",
author = "Chen, {Bihong T.} and Taihao Jin and Patel, {Sunita K.} and Ningrong Ye and Sun, {Can Lan} and Huiyan Ma and Rockne, {Russell C.} and Root, {James C.} and Andrew Saykin and Ahles, {Tim A.} and Holodny, {Andrei I.} and Neal Prakash and Joanne Mortimer and James Waisman and Yuan Yuan and Daneng Li and George Somlo and Jessica Vazquez and Abrahm Levi and Heidi Tan and Richard Yang and Vani Katheria and Arti Hurria",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10549-018-4911-y",
language = "English (US)",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer

AU - Chen, Bihong T.

AU - Jin, Taihao

AU - Patel, Sunita K.

AU - Ye, Ningrong

AU - Sun, Can Lan

AU - Ma, Huiyan

AU - Rockne, Russell C.

AU - Root, James C.

AU - Saykin, Andrew

AU - Ahles, Tim A.

AU - Holodny, Andrei I.

AU - Prakash, Neal

AU - Mortimer, Joanne

AU - Waisman, James

AU - Yuan, Yuan

AU - Li, Daneng

AU - Somlo, George

AU - Vazquez, Jessica

AU - Levi, Abrahm

AU - Tan, Heidi

AU - Yang, Richard

AU - Katheria, Vani

AU - Hurria, Arti

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy in older women with breast cancer. Methods: We recruited 16 women aged ≥ 60 years with stage I–III breast cancers receiving adjuvant chemotherapy (CT) and 15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry. Results: The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically significantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, and left middle temporal gyrus (pFWE(family-wise error)-corrected < 0.05). The baseline GMD in left insula was positively correlated with the baseline list-sorting working memory score in the HC group (pFWE-corrected < 0.05). No correlation was observed for the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (pFWE-corrected < 0.05). Conclusions: Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is registered on ClinicalTrials.gov (NCT01992432).

AB - Purpose: The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy in older women with breast cancer. Methods: We recruited 16 women aged ≥ 60 years with stage I–III breast cancers receiving adjuvant chemotherapy (CT) and 15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry. Results: The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically significantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, and left middle temporal gyrus (pFWE(family-wise error)-corrected < 0.05). The baseline GMD in left insula was positively correlated with the baseline list-sorting working memory score in the HC group (pFWE-corrected < 0.05). No correlation was observed for the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (pFWE-corrected < 0.05). Conclusions: Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is registered on ClinicalTrials.gov (NCT01992432).

KW - Breast cancer

KW - Chemotherapy

KW - Cognition

KW - Gray matter density (GMD)

KW - Voxel-based morphometry (VBM)

UR - http://www.scopus.com/inward/record.url?scp=85051277789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051277789&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4911-y

DO - 10.1007/s10549-018-4911-y

M3 - Article

C2 - 30088178

AN - SCOPUS:85051277789

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -